Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a $6.3B biotechnology company trading at $102.99. Figures from SEC EDGAR and market feeds; updated 2026-09-05 16:27 UTC.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a $6.3B biotechnology company trading at $102.99. Figures from SEC EDGAR and market feeds; updated 2026-09-05 16:27 UTC.
Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases with three approved medicines: Livmarli for cholestatic pruritus and progressive familial intrahepatic cholestasis, Cholbam for bile acid synthesis disorders and peroxisomal disorders, and Ctexli for cerebrotendinous xanthomatosis. The company markets these medicines in the United States, Canada, and select European countries through its own commercial team, and has entered into license and distribution agreements for additional territories.
Summarized from Mirum Pharmaceuticals, Inc.’s SEC filings · Read the filing ↗
| Quote | |
| Price | $102.99 |
| Market cap | $6.3B |
| Volume | 120.1K shares |
| Valuation | |
| EPS (TTM) | $-0.47 |
| Price/book | 19.96× |
Mirum Pharmaceuticals, Inc. is a biotechnology company, listed on NASDAQ as MIRM.
MIRM trades at $102.99, as of 2026-09-05.
Mirum Pharmaceuticals, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-08-05. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings and public market data feeds, fetched 2026-09-05 16:27 UTC. This page is also available as JSON at /api/data?ticker=MIRM and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for MIRM and 5,000+ tickers.
Create a free account — keep MIRMGET /api/data?ticker=MIRM
This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt